Dose-dense chemotherapy with the CODE combination (CDDP–VCR–ADM–ETP), combined with granulocyte colony-stimulating factor (G-CSF), has been shown to be safe when administered to patients with advanced lung cancer (Murray et al, 1991; Fukuoka et al, 1997). The gene discussed is CSF3; the disease is lung cancer.